Support teaching, research, and patient care.
I have over two decades worth of experience in developing and applying high-throughput and high-resolution genomics analysis tools and procedures, in particular in the context of studying genomic sequence variation in brain development and function. I have been involved on numerous occasions in using a large-scale and high-throughput setup for genomics analyses as well as carrying out analyses over several levels of genomics and epigenomics information. This includes participation in the ENCODE and 1000 Genomes projects, for the latter as a member of both the analytical and structural variation groups. I have experience with developing and applying state-of-the-art and emerging genomics and epigenomics technologies (array and next-generation-sequencing based) for the analysis of gene expression, genomic DNA sequence and structure, DNA methylation and chromatin modification, in human cells and human cell culture systems, including stem cell culture models. For example I was co-first author of the paper in Science (Korbel, Urban, Affourtit et al., 2007, PMID 17901297) on developing next-generation-sequencing based paired-end mapping of CNVs and SVs, an approach that is now a standard part of whole-human-genome sequencing projects such as the 1000 Genomes Project. Paired-end mapping is also a critical component of advanced RNA-Seq approaches, mapping of transposable elements and the study of long-range chromatin interactions using the HiC method. Two main, and connected, directions of research in my laboratory are the investigation of the molecular effects of large genome variants during neuronal development using iPSC model systems and the study of the nature and effects of somatic genome variation in the brain using tissue culture models and primary tissue samples.
Building Resilience at Schools: Emotional and Biological Assessment and Treatment of Traumatic Stress
In the last four years alone, residents of Puerto Rico have experienced a slew of natural
disasters including Hurricane Maria in 2017, earthquakes in 2019 and 2020, the continued
COVID-19 pandemic from 2020-2022, and most recently Hurricane Fiona. This series of
distressing events can lead to an increased need for mental health resources and trauma
treatment. Furthermore, the unique single-district structure of the Puerto Rican education
system allows for the efficient dissemination of potential interventions and treatment to all
The purpose of this study is to examine two treatment conditions for educators and
school-aged children in Puerto Rico experiencing burnout, fatigue, and high stress: delivery
of a mindfulness-based educator curriculum and, for children who report Post Traumatic Stress
Disorder (PTSD) symptomatology, delivery of the mindfulness curriculum with the additional
intervention of Cue-Centered Therapy (CCT). The study has two aims: 1) To assess the efficacy
of the mindfulness curriculum and of CCT in a population of students, counselors, and
teachers, characterized by high stress over the last few years of natural disasters and
pandemic challenges and 2) To identify genetic contributions to resilience by analyzing gene
expression in students before and after the intervention.
The overarching goals of the investigators' research collaboration are to improve educators'
psychological well-being and children's socioemotional development when faced with high
stress and adversity and to improve mental health clinicians' competence and confidence in
treating children exposed to trauma by training them in CCT. The investigators' research will
identify critical biopsychosocial components responsible for the cognitive, behavioral, and
emotional improvement and effective implementation strategies in a large but geographically
dispersed school district. The knowledge base that will result from this study will inform
the implementation of trauma-informed care in school settings and with populations
experiencing stress and adversity, and contribute to the investigators' understanding of the
underlying biology of these interventions to provide a rationale for further development and
Stanford is currently not accepting patients for this trial.
For more information, please contact Emily Wu, 650-724-6598.
View full details